Bottom line: MCCS and NIH-CI are comparable and add prognostic signal beyond clinical data—with IF/TA doing most of the heavy lifting—and performance was consistent in Class V LN. MCCS may offer a practical edge by aligning chronicity grading across glomerular diseases.
In lupus nephritis (LN), “activity” gets the spotlight—but chronic scarring often decides the long game. So: which chronicity score best predicts outcomes—NIH Chronicity Index (NIH-CI) or the Mayo Clinic Chronicity Score (MCCS)?
https://t.co/eyt9txJqQr
Why should it replace the current NIH chronicity score?
- It is universal, tested in other glomerulopathies, not just lupus nephritis.
- It includes chronic damage to the vascular compartment (not just the glomerulus, interstitium, and tubules). Namely, arteriosclerosis.
I scored > 300 lupus nephritis biopsies for chronicity indices with Maria Gutierrez/Chile.
Bx scoring was simple: minimal, mild, moderate, severe.
The chronicity score correlates very well with outcomes/prognosis.
Score should be included in Bx report.
https://t.co/IIC763OFOn
I scored > 300 lupus nephritis biopsies for chronicity indices with Maria Gutierrez/Chile.
Bx scoring was simple: minimal, mild, moderate, severe.
The chronicity score correlates very well with outcomes/prognosis.
Score should be included in Bx report.
https://t.co/IIC763OFOn
I scored > 300 lupus nephritis biopsies for chronicity indices with Maria Gutierrez/Chile.
Bx scoring was simple: minimal, mild, moderate, severe.
The chronicity score correlates very well with outcomes/prognosis.
Score should be included in Bx report.
https://t.co/IIC763OFOn
In 2020 Beck et al. described the #VEXAS syndrome.
✨We are now excited to share our latest paper - a first systematic review of the literature on treatment strategies for VEXAS published in @RheumJnl📚
https://t.co/nV8ydsRaWC